Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ascletis Pharma Inc.
Industry Sector: HealthTechnology
CEO: Jinzi J. Wu, PhD
Number Of Employees: 231
Enterprise Value: $122,265,580
PE Ratio: -19.95
Exchange/Ticker 1: HKEX:1672
Exchange/Ticker 2: N/A
Latest Market Cap: $808,665,858
BioCentury | Feb 20, 2025
Product Development
Solid produces best-in-class biomarker data among DMD gene therapies
BioCentury’s latest Clinical Report highlights a pair of value-driving readouts
BioCentury | May 3, 2023
Deals
May 2 Quick Takes: Janssen paying CBMG $245M for CAR T rights
Plus: Delay in Senate for drug pricing votes plus updates from Ten63, FDA, Immatics, Travere, Ascletis and more
BioCentury | Oct 28, 2022
Product Development
Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings
Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more
BioCentury | Jun 14, 2022
Management Tracks
McCracken named CEO at Evonetix
Plus Pirzkall becomes CMO at Asher, and updates from Domain, Syndax,
BioCentury | Mar 10, 2021
Product Development
March 9 Quick Takes: Novartis’ canakinumab misses in Phase III NSCLC trial; plus Acadia, Cognito, Sagimet-Ascletis, GreenLight and Visus
Nearly four years after detecting an association between canakinumab therapy and decreased incidence of lung cancer in a clinical trial for atherosclerosis, Novartis AG (SIX:NOVN; NYSE:NVS) said the
BioCentury | Feb 23, 2021
Product Development
Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor
Sanofi (Euronext:SAN; NASDAQ:SNY) will formulate and fill about 12 million doses per month of the single-shot COVID-19 vaccine from Johnson & Johnson (NYSE:JNJ) following authorization. The
BioCentury | Feb 13, 2021
Deals
Feb. 12 Quick Takes: NexImmune, Decibel rise in NASDAQ debuts; plus Sagimet’s $80M crossover, Forbion launches VectorY, Aurora Science leads InteRNA round and a SPAC for Sharecare
Shares of NexImmune Inc. (NASDAQ:NEXI) and Decibel Therapeutics Inc. (NASDAQ:DBTX) traded higher Friday after the companies priced IPOs on NASDAQ Thursday night. Hearing and balance therapy
BioCentury | Nov 30, 2020
Management Tracks
New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH
Ascletis is looking to Takeda veteran Melissa Palmer to move its pipeline of in-licensed and homegrown NASH programs forward. Ascletis Pharma Inc. (HKEX:1672) announced Monday that Palmer, the
BioCentury | Aug 1, 2020
Product Development
July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck
BioCentury | May 23, 2020
Finance
Proposed legislation could deter Chinese biotechs from listing in U.S.
U.S. bill seeking to tighten auditing rules for foreign companies could be win for HKSE
Items per page:
1 - 10 of 107